LogicBio Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LogicBio Therapeutics, Inc.
How To Turn Around A Struggling Biotech
Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.
Andera Bullish About Prospects For Europe's Biotechs
The France-based firm has assembled a strong syndicate for its sixth generation of 'BioDiscovery' funds, consolidating its position as one of the leading players in life sciences venture capital in Europe.
AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
The IPO Party Is Over – How Bad Is The Hangover?
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Alexion Pharmaceuticals Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.